<DOC>
	<DOCNO>NCT01574235</DOCNO>
	<brief_summary>The main aim study assess safety Nivestim® treatment patient treat neutropenia-inducing chemotherapy malignant disease , solid tumor malignant hemopathy .</brief_summary>
	<brief_title>Nivestim® ( Filgrastim ) Tolerance Patients Treated Toxic Chemotherapeutic Agents</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
	<criteria>Age ≥ 18 year Patients present solid tumor malignant hemopathy , Patients treat begin treatment neutropeniainducing chemotherapy ( regardless cycle ) , Patients treatment Nivestim® institute purpose reduce duration neutropenia incidence chemotherapyinduced febrile neutropenias Patients present chronic myeloproliferative syndrome , Patients present myelodysplastic syndrome , Patients show hypersensitivity ingredient Nivestim® , Patients receive chemotherapy , Patients already include study previous chemotherapy line</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>